CLAIMS

1. A conjugate of a fusion protein and a drug, wherein the fusion protein comprising a vascular endothelial growth factor receptor 1 (VEGFR1) and an antibody Fc region, wherein the fusion protein is ordered from N-terminus to C-terminus in the order VEGFR1 then antibody Fc region,

wherein the VEGFR1 comprises a VEGFR1 domain 2 and a VEGFR1 domain 3,

wherein the drug is fused to a N-terminus of the fusion protein.

2. The conjugate according to claim 1, wherein the VEGFR1 domain 3 comprising the amino acid sequence of SEQ ID NO: 29.

3. The conjugate according to claim 1, wherein the drug is an anti-cancer agent or a therapeutic agent for angiogenesis-related disease,

wherein the angiogenesis-related disease is tumor growth and metastasis, diabetic retinopathy, premature retinopathy, corneal graft rejection, neovascular glaucoma, erythrosis, proliferative retinopathy, psoriasis, macular degeneration, hemophiliac joints, capillary proliferation within atherosclerotic plaques, keloid, wound granulation,

vascular adhesion, rheumatoid arthritis, chronic inflammation, osteoarthritis, autoimmune disease, Crohn's disease, restenosis, atherosclerosis, intestinal stenosis, cat scratch disease, ulcers, cirrhosis complications, glomerulonephritis, diabetic nephropathy, malignant nephrosclerosis, thrombotic micro vascular syndrome, organ transplant rejection, glomerulopathy, diabetes, inflammation, neurodegeneration, aging-related macular degeneration, exudative aging-related macular degeneration, choroidal neovascularization, pathological myopia, macular edema or retinal vein occlusion.

4. The conjugate according to claim 1, wherein the drug is an antibody capable of binding to epidermal growth factor receptor (EGFR) or human epidermal growth factor receptor type2 (HER2).

5. The conjugate according to claim 1, wherein the drug is cetuximab or trastuzumab.

6. The conjugate according to claim 1, wherein the drug has a form selected from the group consisting of scFv, dsFv, Fab, Fab', $F(ab')_2$, and nanobody, wherein the forms being antigen recognition sites.

7. A polynucleotide encoding the conjugate according to any one of claims 1 to 6.

8. An expression vector comprising the polynucleotide of claim 7.

9. A transformant comprising the expression vector of claim 8.

10. A method of producing a conjugate, comprising culturing the transformant of claim 9.

11. The conjugate according to claim 1, wherein the conjugate is comprised in a pharmaceutical composition suitable for preventing or treating cancer or angiogenesis-related disease, wherein the angiogenesis-related disease is tumor growth and metastasis, diabetic retinopathy, premature retinopathy, corneal graft rejection, neovascular glaucoma, erythrosis, proliferative retinopathy, psoriasis, macular degeneration, hemophiliac joints, capillary proliferation within atherosclerotic plaques, keloid, wound granulation, vascular adhesion, rheumatoid arthritis, chronic inflammation, osteoarthritis, autoimmune disease, Crohn's disease, restenosis, atherosclerosis, intestinal stenosis, cat scratch disease, ulcers, cirrhosis complications,

glomerulonephritis, diabetic nephropathy, malignant nephrosclerosis, thrombotic micro vascular syndrome, organ transplant rejection, glomerulopathy, diabetes, inflammation, neurodegeneration, aging-related macular degeneration, exudative aging-related macular degeneration, choroidal neovascularization, pathological myopia, macular edema or retinal vein occlusion.

12. The conjugate according to claim 11, wherein the cancer is liver cancer, lung cancer, pancreatic cancer, non-small cell lung cancer, colon cancer, bone cancer, skin cancer, head or neck cancer, skin or intraocular melanoma, uterine cancer, ovarian cancer, rectal cancer, gastric cancer, anal muscle cancer, breast cancer, fallopian tube carcinoma, endometrial carcinoma, cervical carcinoma, vaginal carcinoma, vulva carcinoma, Hodgkin's disease, esophageal cancer, small intestine cancer, endocrine adenocarcinoma, thyroid cancer, parathyroid cancer, adrenal cancer, soft-tissue sarcoma, urethral cancer, penile cancer, prostate cancer, chronic or acute leukemia, lymphocytic lymphoma, bladder cancer, kidney or ureter cancer, renal cell carcinoma, renal pelvic carcinoma, central nervous system (CNS) tumor, primary central nervous system lymphoma, spinal cord tumor, brain stem glioma, or pituitary adenoma.